Roche Holding AG (RHHBY) on Monday said its Elecsys Neurofilament Light Chain (NfL) Test has received CE mark approval for detecting neuroinflammation in patients with relapsing remitting multiple sclerosis.
The simple blood test is designed to detect neuroaxonal damage linked to neuroinflammation in adults with multiple sclerosis, offering a less invasive alternative to traditional diagnostic methods.
"The availability of a simple blood-based test has the potential to complement resource-intensive MRI scans and improve access for patients with RRMS. The Elecsys NfL test will help healthcare providers support timely clinical reassessment, enabling better disease management and more personalised care for patients," said Matt Sause, CEO of Roche Diagnostics.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.